Overview
- TickerIMTX on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersTübingen1
- Websitewww.immatics.com
- Incorporated inNetherlands5
- Business addressPaul Ehrlich-Strasse 15, Tubingen, 2M 720765
- Filer categoryAccelerated filer5
See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue from collaboration agreements | 48.3M EUR | 155.8M EUR | 54.0M EUR |
| Research and development expenses | -183.8M EUR | -148.1M EUR | -118.7M EUR |
| General and administrative expenses | -51.2M EUR | -46.4M EUR | -38.2M EUR |
| Other income | 4.7M EUR | 78.0K EUR | 1.1M EUR |
| Operating result | -182.0M EUR | -38.6M EUR | -101.7M EUR |
| Change in fair value of liabilities for warrants | 1.7M EUR | 17.3M EUR | -2.1M EUR |
| Other financial income | 18.5M EUR | 44.0M EUR | 13.8M EUR |
| Other financial expenses | -36.7M EUR | -1.3M EUR | -7.0M EUR |
| Financial result | -16.4M EUR | 60.0M EUR | 4.7M EUR |
| Profit/(loss) before taxes | -198.4M EUR | 21.3M EUR | -97.0M EUR |
| Taxes on income | 2.0M EUR | -6.1M EUR | 2.3M EUR |
| Net profit/(loss) | -196.4M EUR | 15.2M EUR | -94.6M EUR |
| Basic | -1.61 EUR | 0.14 EUR | -1.18 EUR |
| Diluted | -1.61 EUR | 0.14 EUR | -1.18 EUR |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | 345.9M EUR | 236.7M EUR | 218.5M EUR |
| Other financial assets | 123.4M EUR | 367.7M EUR | |
| Accounts receivables | 6.1M EUR | 5.9M EUR | |
| Other current assets | 28.6M EUR | 19.2M EUR | |
| Total current assets | 504.0M EUR | 629.6M EUR | |
| Property, plant and equipment | 42.1M EUR | 50.4M EUR | |
| Intangible assets | 1.6M EUR | 1.6M EUR | |
| Right-of-use assets | 12.8M EUR | 13.3M EUR | |
| Other non-current assets | 1.9M EUR | 1.2M EUR | |
| Total non-current assets | 58.3M EUR | 66.6M EUR | |
| Total assets | 562.3M EUR | 696.1M EUR | |
| Accounts payables | 18.8M EUR | 20.7M EUR | |
| Deferred revenue | 15.8M EUR | 35.9M EUR | |
| Liabilities for warrants | 0 EUR | 1.7M EUR | |
| Lease liabilities | 2.8M EUR | 2.9M EUR | |
| Other current liabilities | 5.6M EUR | 6.8M EUR | |
| Total current liabilities | 43.0M EUR | 68.0M EUR | |
| Deferred revenue | 18.5M EUR | 34.2M EUR | |
| Lease liabilities | 12.9M EUR | 13.4M EUR | |
| Deferred tax liability | 3.8M EUR | 5.8M EUR | |
| Total non-current liabilities | 35.2M EUR | 53.3M EUR | |
| Share capital | 1.3M EUR | 1.2M EUR | |
| Share premium | 1.3B EUR | 1.2B EUR | |
| Accumulated deficit | -786.0M EUR | -589.5M EUR | |
| Other reserves | -8.6M EUR | 1.0M EUR | |
| Total shareholders' equity | 484.1M EUR | 574.8M EUR | 217.6M EUR |
| Total liabilities and shareholders' equity | 562.3M EUR | 696.1M EUR |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net profit/(loss) | -196.4M EUR | 15.2M EUR | -94.6M EUR |
| Taxes on income | -2.0M EUR | 6.1M EUR | -2.3M EUR |
| Profit/(loss) before tax | -198.4M EUR | 21.3M EUR | -97.0M EUR |
| Interest income | -17.2M EUR | -25.0M EUR | -13.8M EUR |
| Depreciation and amortization | 12.4M EUR | 12.2M EUR | 7.2M EUR |
| Interest expenses | 946.0K EUR | 886.0K EUR | 831.0K EUR |
| Equity settled share-based payment | 15.0M EUR | 17.6M EUR | 20.7M EUR |
| Net foreign exchange differences and expected credit losses | 34.1M EUR | -18.7M EUR | 6.9M EUR |
| Change in fair value of liabilities for warrants | -1.7M EUR | -17.3M EUR | 2.1M EUR |
| (Gains)/losses from disposal of fixed assets | 750.0K EUR | 1.0K EUR | -150.0K EUR |
| (Increase)/decrease in accounts receivables | -242.0K EUR | -1.8M EUR | -3.0M EUR |
| (Increase)/decrease in other assets | -6.1M EUR | 727.0K EUR | 1.6M EUR |
| Increase/(decrease) in deferred revenue, accounts payables and other liabilities | -37.6M EUR | -149.7M EUR | 86.0M EUR |
| Interest received | 26.8M EUR | 15.6M EUR | 10.2M EUR |
| Interest paid | -946.0K EUR | -886.0K EUR | -290.0K EUR |
| Income tax paid | -9.2M EUR | -13.1M EUR | -3.0M EUR |
| Income tax refunded | 4.7M EUR | ||
| Net cash provided by/(used in) operating activities | -176.6M EUR | -158.0M EUR | 18.2M EUR |
| Payments for property, plant and equipment | -6.6M EUR | -16.3M EUR | -30.8M EUR |
| Payments for intangible assets | -247.0K EUR | -208.0K EUR | -158.0K EUR |
| Proceeds from disposal of property, plant and equipment | 2.0K EUR | 150.0K EUR | |
| Payments for investments classified in Other financial assets | -338.3M EUR | -450.3M EUR | -415.3M EUR |
| Proceeds from maturity of investments classified in Other financial assets | 549.9M EUR | 314.4M EUR | 414.7M EUR |
| Net cash (used in)/provided by investing activities | 204.8M EUR | -152.4M EUR | -31.4M EUR |
| Proceeds from issuance of shares to equity holders | 107.3M EUR | 343.0M EUR | 90.4M EUR |
| Transaction costs deducted from equity | -7.0M EUR | -21.3M EUR | -2.0M EUR |
| Repayment of lease liabilities | -3.0M EUR | -2.0M EUR | -3.8M EUR |
| Net cash provided by/(used in) financing activities | 97.4M EUR | 319.7M EUR | 84.5M EUR |
| Net increase/(decrease) in cash and cash equivalents | 125.5M EUR | 9.3M EUR | 71.4M EUR |
| Effects of exchange rate changes and expected credit losses on cash and cash equivalents | -16.3M EUR | 9.0M EUR | -1.4M EUR |
Compare Immatics Biotechnologies (Germany) with another company
Leadership
Who has led Immatics Biotechnologies (Germany), and when. Pick a name to see everywhere that person has worked.
Board members and other officers (1)
- Vice presidentClaudia Thilo1
Former names
- Immatics B.V.Apr 16, 2020 to Jul 8, 20205
Timeline
Recent filings
- Aug 27, 2026SCHEDULE 13D/A
- Aug 27, 20264
- Aug 26, 20266-K
- Aug 25, 2026424B2
- Aug 18, 20266-K
- Aug 18, 20264
- Aug 14, 2026SCHEDULE 13G/A
- Jul 29, 20263
- Jun 25, 2026S-8
- Jun 18, 20266-K
- Jun 18, 20264
- Jun 18, 20264
- Jun 18, 20264
- Jun 18, 20264
- Jun 18, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- WikidataQ30256960
- SEC EDGARCIK 1809196
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3Company websiteImmatics Biotechnologies (Germany) logo
- 4
- 5
- 6
- 7
- 8
- 9
- 10